Hookipa Pharma
Hookipa Pharma.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 25.3x EV/Revenue -5.9x EV/EBITDA | round | |
| N/A | €0.0 | round | |
* | $21.3m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (46 %) | 57 % | 64 % | (6 %) | (23 %) | 41 % | 118 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (194 %) | (428 %) | (272 %) | (443 %) | (513 %) | (321 %) | (78 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (213 %) | (360 %) | (225 %) | (410 %) | (456 %) | (405 %) | (99 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 288 % | 388 % | 280 % | 449 % | 482 % | 429 % | 156 % |
Source: Company filings or news article
Related Content
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of immunotherapeutics. These therapeutics are designed to target infectious diseases and cancers by leveraging the company's proprietary arenavirus platform, which aims to reprogram the immune system to fight these conditions more effectively. The company primarily serves the healthcare sector, including patients, healthcare providers, and research institutions. Operating in the biopharmaceutical market, HOOKIPA's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, grants, and future product sales. The company is headquartered in New York, USA, and Vienna, Austria, and is publicly traded on NASDAQ under the ticker symbol HOOK.
Keywords: immunotherapeutics, infectious diseases, cancers, arenavirus platform, immune system, biopharmaceutical, clinical-stage, healthcare, research, NASDAQ.